Literature DB >> 22858928

The FDA-mandated trial of safety of long-acting beta-agonists in asthma: finality or futility?

Malcolm R Sears1.   

Abstract

Mesh:

Substances:

Year:  2012        PMID: 22858928     DOI: 10.1136/thoraxjnl-2012-202414

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


× No keyword cloud information.
  4 in total

Review 1.  Long-Acting β2-Agonists in Asthma: Enantioselective Safety Studies are Needed.

Authors:  Glenn A Jacobson; Sharanne Raidal; Morten Hostrup; Luigino Calzetta; Richard Wood-Baker; Mark O Farber; Clive P Page; E Haydn Walters
Journal:  Drug Saf       Date:  2018-05       Impact factor: 5.606

2.  Prescribing of long-acting beta-2-agonists/inhaled corticosteroids after the SMART trial.

Authors:  Marietta Rottenkolber; Rainald Fischer; Luisa Ibáñez; Joan Fortuny; Robert Reynolds; Justyna Amelio; Roman Gerlach; Martin Tauscher; Petra Thürmann; Joerg Hasford; Sven Schmiedl
Journal:  BMC Pulm Med       Date:  2015-05-06       Impact factor: 3.317

Review 3.  Can the anti-inflammatory activities of β2-agonists be harnessed in the clinical setting?

Authors:  Annette J Theron; Helen C Steel; Gregory R Tintinger; Charles Feldman; Ronald Anderson
Journal:  Drug Des Devel Ther       Date:  2013-11-22       Impact factor: 4.162

4.  The beta-2-adrenoreceptor agonists, formoterol and indacaterol, but not salbutamol, effectively suppress the reactivity of human neutrophils in vitro.

Authors:  Ronald Anderson; Annette J Theron; Helen C Steel; Chrisna Durandt; Gregory R Tintinger; Charles Feldman
Journal:  Mediators Inflamm       Date:  2014-03-06       Impact factor: 4.711

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.